Drugs for preventing red blood cell dehydration in people with sickle cell disease

Nagalla, Srikanth; Ballas, Samir K.

doi:10.1002/14651858.cd003426.pub5

Cited by 13 publications

(2 citation statements)

References 68 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to research related to enhancing Hgb F levels, there are studies investigating other treatments that may prevent or reduce the severity of sickle cell pain. These include anti-adhesion agents (Kutlar et al, 2012) and agents that prevent dehydration in sickle red blood cells (Nagalla & Ballas, 2012). While research on the best way to manage sickle cell pain is important, the research priority should be the development of antisickling agents, so that sickle cell pain and organ damage can be prevented (“Anti-sickling therapies,” 2013)…”

Section: Discussionmentioning

confidence: 99%

Perception of Pain Among Pediatric Patients With Sickle Cell Pain Crisis

Fosdal

2014

J Pediatr Oncol Nurs

View full text Add to dashboard Cite

Pain related to vasoocclusion is the most common reason for emergency department visits and hospital stays among pediatric patients with sickle cell disease. Using a prospective descriptive design, patients hospitalized with sickle cell pain were asked to complete the Adolescent Pediatric Pain Tool on each day of their hospital stay, providing data on the location, intensity, and quality of their pain. Data for 82 hospital stays were collected from 40 African American study participants. Mean age was 14.8 years, and mean length of stay (LOS) was 5.1 days. Mean LOS for 8 to 12 year olds (3.23 days; n = 22) was shorter than mean LOS for 13 to 19 year olds (5.85 days; n = 60). This LOS difference was significant (P = .004). Difference in LOS by gender was not significant. Higher initial number of body sites with pain was significantly associated with longer LOS (r = .39; P < .001). Higher initial pain intensity scores were significantly associated with longer LOS (r = .37; P = .001). Higher initial number of word descriptors was only weakly associated with longer LOS. Neither gender nor age differences were significant for Adolescent Pediatric Pain Tool data.

show abstract

Section: Discussionmentioning

confidence: 99%

Perception of Pain Among Pediatric Patients With Sickle Cell Pain Crisis

Fosdal

2014

J Pediatr Oncol Nurs

View full text Add to dashboard Cite

show abstract

“…For relevant discussions, see Yakoob et al [ 9 ] Brown et al [ 13 ], Zeng and Zhang [ 10 ], Sigfried [ 68 ], Humphreys [ 69 ], Islam and Loots [ 70 ],. Lai et al [ 71 ], Nagala et al [ 72 ], Kulier et al [ 73 ], and Worthington et al [ 74 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluating the cost-effectiveness of preventive zinc supplementation

Fink

Heitner

2014

BMC Public Health

View full text Add to dashboard Cite

BackgroundEven though the WHO currently recommends zinc for diarrhea management, no consensus has been reached with respect to routine distribution of zinc for preventive reasons. We reviewed the health impact of preventive zinc interventions, and evaluated the relative cost effectiveness of currently feasible interventions.MethodsUsing the latest relative risk estimates reported in the literature, we parameterized a health impact model, and calculated the expected benefits of zinc supplementation in a representative low-income country. We then computed the cost and cost-effectiveness for three delivery mechanisms: the direct distribution of zinc supplements, the distribution of micronutrient biscuits including zinc, and the distribution of zinc through water filtration systems.ResultsCombining all health outcomes and impact estimates, we find that systematic zinc supplementation among children of ages one to five would avert 1.423 DALYs per 100 households and year in least developed countries. The estimated cost per DALY is US$ 606 for pill supplementation, US$ 1211 for micronutrient biscuits, and US$ 879 per DALY saved for water filtration systems.ConclusionsPreventive zinc supplementation to children of ages 1–5 appears to be a highly cost-effective intervention in typical developing country settings. More research will be needed to determine the most effective mechanism to deliver zinc to this target population.

show abstract

Drugs for preventing red blood cell dehydration in people with sickle cell disease

Nagalla

Ballas

2018

Cochrane Database of Systematic Reviews

Self Cite

View full text Add to dashboard Cite

Background Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications. Recent research has focused on therapies to rehydrate the sickled cells by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs. This is an updated version of a previously published review. Objectives To assess the relative risks and benefits of drugs to rehydrate sickled red blood cells. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register. We also searched online trials registries for any ongoing trials (01 July 2018).

show abstract

Drugs for preventing red blood cell dehydration in people with sickle cell disease

Abstract: Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group. Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 3, 2016. Review content assessed as up-to-date: 4 March 2016.

Cited by 13 publications

References 68 publications

Perception of Pain Among Pediatric Patients With Sickle Cell Pain Crisis

Perception of Pain Among Pediatric Patients With Sickle Cell Pain Crisis

Evaluating the cost-effectiveness of preventive zinc supplementation

Drugs for preventing red blood cell dehydration in people with sickle cell disease

Contact Info

Product

Resources

About